NCT00798135

A Pilot Trial of Itraconazole Pharmacokinetics in Patients With Metastatic Breast Cancer

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 13 (actual)
• Sponsor: Indiana University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Cancer cells need to be able to make new blood vessels in order to keep growing. This is called angiogenesis. In a laboratory setting, the drug itraconazole was shown to help stop the growth of new blood vessels (anti-angiogenesis). It is hoped that itraconazole will prevent new blood vessels from forming in humans too. The purpose of this study is to look at how the body processes and breaks down itraconazole (called pharmacokinetics). This study will also measure markers in your blood to see if itraconazole stops new blood vessels from forming. The safety of itraconazole will also be tested to see what effects (good and bad) it has on you and your breast cancer.

Conditions

• Breast Neoplasms
• Neoplasm Metastasis

Interventions

Type	Name	Description
DRUG	itraconazole	oral itraconazole 200mg a day until disease progression or unacceptable toxicities.

Timeline

• Start date: 2008-11-01
• Primary completion: 2012-02-01
• Completion: 2012-03-01
• First posted: 2008-11-25
• Last updated: 2023-12-21
• Results posted: 2014-09-10

Locations

1 site across 1 country: United States